The Rising Influence of Rising Affluence

[DewDiligence]

PFE—FDA_panel_votes_18-0_for_booster_EUA_for_ age_65+_and_high-risk_individuals:

FDA writes a new question for the committee, after advisers rejected broad booster use.

Notably, this question is for *emergency authorization* of a third dose of Pfizer's vaccine, NOT approval as Pfizer had applied for. pic.twitter.com/bkdo3oMod2

— Ned Pagliarulo (@NedPagliarulo) September 17, 2021

Initially, the FDA advisory panel rejected a booster for the general adult population (age 16+).